The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of included studies.

Studies	Year	Intervention		Number (case/control)	Type of study
		Experimental group	Control group
Cortot et al.	2020	Bevacizumab+paclitaxel	Docetaxel	111/55	RCT
Kitagawa et al.	2019	Bevacizumab+gefitinib	Gefitinib	6/10	RCT
Fukuda et al.	2019	Bevacizumab+pemetrexed	Pemetrexed	20/20	RCT
Saito et al.	2019	Bevacizumab+erlotinib	Erlotinib	114/114	RCT
Karayama et al.	2016	Bevacizumab+pemetrexed	Pemetrexed	55/55	RCT
Seto et al.	2014	Bevacizumab+erlotinib	Erlotinib	77/77	RCT
Niho et al.	2012	Bevacizumab+carboplatin+paclitaxel	Carboplatin+paclitaxel	121/59	RCT
Reck et al.	2010	Bevacizumab 7.5 mg/kg+cisplatin+gemcitabine	Placebo+cisplatin+gemcitabine	345/347	RCT
Reck et al.	2009	Bevacizumab 15 mg/kg+cisplatin+gemcitabine	Placebo+cisplatin+gemcitabine	351/347	RCT
Sandler et al.	2006	Bevacizumab+paclitaxel+carboplatin	Paclitaxel+carboplatin	417/433	RCT

RCT: randomized controlled trial.